Browse > Article

Acute Respiratory Distress Syndrome after Topotecan Therapy in a Patient with Small Cell Lung Cancer  

Tae, Jung Hyun (Department of Internal Medicine, Ewha Womans University School of Medicine)
Lee, Jin Hwa (Department of Internal Medicine, Ewha Womans University School of Medicine)
Kim, Yoon Kyung (Department of Radiology, Ewha Womans University School of Medicine)
Sim, Yun Su (Department of Internal Medicine, Ewha Womans University School of Medicine)
Lee, Kyung Jong (Department of Internal Medicine, Ewha Womans University School of Medicine)
Noh, Young Wook (Department of Internal Medicine, Ewha Womans University School of Medicine)
Park, Jae Jung (Department of Internal Medicine, Ewha Womans University School of Medicine)
Ryu, Yon Ju (Department of Internal Medicine, Ewha Womans University School of Medicine)
Chun, Eun Mi (Department of Internal Medicine, Ewha Womans University School of Medicine)
Chang, Jung Hyun (Department of Internal Medicine, Ewha Womans University School of Medicine)
Publication Information
Tuberculosis and Respiratory Diseases / v.65, no.2, 2008 , pp. 142-146 More about this Journal
Abstract
Small cell lung cancer is characterized by an aggressive clinical course and a high tendency for early dissemination in spite of a good chemotherapy response. Topotecan is a topoisomerase I inhibitor, and it is used as second-line treatment for small cell lung cancer. The reported dose-limiting adverse reactions to topotecan are mainly hematologic. Yet pulmonary toxicity associated with topotecan is known to be rare. We report here on a case that showed the development of acute respiratory distress syndrome during the 3rd cycle of topotecan chemotherapy in a patient with small cell lung cancer. He developed dyspnea and respiratory failure, and the chest CT scan revealed diffuse ground-glass opacity that was probably due to chemotherapy-related pulmonary toxicity. He finally died of acute respiratory distress syndrome.
Keywords
Small cell carcinoma; Topotecan; Acute respiratory distress syndrome;
Citations & Related Records

Times Cited By SCOPUS : 0
연도 인용수 순위
  • Reference
1 Cooper S, Spiro SG. Small cell lung cancer: treatment review. Respirology 2006;11:241-8.   DOI   ScienceOn
2 Rossi SE, Erasmus JJ, McAdams HP, Sporn TA, Goodman PC. Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics 2000;20:1245-59.   DOI
3 Limper AH. Chemotherapy-induced lung disease. Clin Chest Med 2004;25:53-64.   DOI   ScienceOn
4 Maitland ML, Wilcox R, Hogarth DK, Desai AA, Caligiuri P, Abrahams C, et al. Diffuse alveolar damage after a single dose of topotecan in a patient with pulmonary fibrosis and small cell lung cancer. Lung Cancer 2006;54:243-5.   DOI   ScienceOn
5 Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 1992;10:16-20.   DOI
6 Limper AH. Drug-induced pulmonary disease. In: Mason RJ, Broaddus VC, Murray JF, Nadel JA, editors. Murray and Nadel's textbook of respiratory medicine. 4th ed. Philadelphia: Elsevier Saunders; 2005. p. 1888-912.
7 Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed smallcell lung cancer. J Clin Oncol 1992;10:1225-9.   DOI
8 Edgerton CC, Gilman M, Roth BJ. Topotecan-induced bronchiolitis. South Med J 2004;97:699-701.   DOI   ScienceOn
9 Eckardt JR, von Pawel J, Pujol JL, Papai Z, Quoix E, Ardizzoni A, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007;25:2086-92.   DOI   ScienceOn
10 Madarnas Y, Webster P, Shorter AM, Bjarnason GA. Irinotecan-associated pulmonary toxicity. Anticancer Drugs 2000;11:709-13.   DOI
11 Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997;15:2090-6.   DOI
12 Maksymiuk AW, Marschke RF Jr, Tazelaar HD, Grill J, Nair S, Marks RS, et al. Phase II trial of topotecan for the treatment of mesothelioma. Am J Clin Oncol 1998; 21:610-3.   DOI   ScienceOn
13 Malik SW, Myers JL, DeRemee RA, Specks U. Lung toxicity associated with cyclophosphamide use: two distinct patterns. Am J Respir Crit Care Med 1996;154:1851-6.   DOI   ScienceOn
14 MacCallum C, Gillenwater HH. Second-line treatment of small-cell lung cancer. Curr Oncol Rep 2006;8:258-64.   DOI   ScienceOn